Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02220777
Recruitment Status : Completed
First Posted : August 20, 2014
Last Update Posted : August 20, 2014
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:

This is a 4-part study. Part I assesses the safety and tolerability of single ascending doses of ASP8477 or a placebo under fasted conditions in postmenopausal subjects. Part II is similar to part I except that the study is conducted in young, vasectomized males.

Part III assesses the effect of food (fed or fasted conditions) on ASP8477 in postmenopausal subjects.

Part IV assesses the drug-drug interaction between ASP8477 and omeprazole in postmenopausal subjects.


Condition or disease Intervention/treatment Phase
Pharmacokinetics of ASP8477 Pharmacodynamics of ASP8477 Drug: ASP8477 Drug: omeprazole Drug: Placebo Phase 1

Detailed Description:

Part I (SAD) in healthy postmenopausal females evaluates the safety, and tolerability, and defines Maximum Tolerated Dose = MTD, pharmacokinetics, and pharmacodynamics of single ascending oral doses (SAD) of ASP8477. It is anticipated that around 7 doses are required to cover the range from the safe starting dose until the MTD. Study medication is administered under fasted conditions. Based on the safety, PK, and clinical observation of the subjects, the dose escalation scheme may be adapted. Escalation to the next dose only proceeds after review of the safety, tolerability, and PK from the previous treatment period.

Part II (SAD in young, healthy, vasectomized males) is similar to Part I, one cohort of 12 subjects are treated with two doses of ASP8477 plus placebo. The doses tested depend on the safety data and pharmacodynamic profiles obtained in Part I, but is not expected to exceed MTD. The rationale for this part is to bridge the data obtained in female subjects to male subjects.

Part III (food effect) postmenopausal females receive ASP8477 once under fasted and once under fed conditions in two separate periods in random order. The dose does not exceed 1/3 of the MTD or, if that has not been reached, 1/3 of the highest tested dose in Part I. Subjects stay in the clinic for 2 periods of 5 to 7 days (depending on the terminal half life, resulting from Part I). Subjects are admitted on Day -2 per treatment period. Subjects' feeding status is the same as on Day 1 of the same treatment period. Subjects are given a single dose of ASP8477 under fed or fasting conditions on Day 1. After final discharge, subjects return for an End of Study Visit (ESV) 5-9 days later.

Part IV (ASP8477-omeprazole drug-drug interaction) postmenopausal subjects are randomized to receive omeprazole once alone and once with ASP8477 in two separate periods (in random order). The dose of ASP8477 is the MTD or, if that is not been reached, the highest tested dose in Part I. Omeprazole is chosen as target drug as it is a model substrate for CYP2C19 (accepted by FDA) and ASP8477 is known to have the strongest inhibitory effect on CYP2C19. Subjects are admitted on Day -1 and stay for 2 periods of 4 days. Subjects are given a single dose of omeprazole alone or with ASP8477 (in randomized order) on Day 1. Study medication is administered under fasted conditions. Subjects are discharged on Day 3 and return for an ESV 5-9 days later.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of ASP8477 in Healthy Postmenopausal Females and Healthy Young Vasectomized Males, Including a Food Effect Part and a Part to Investigate the Interaction Between ASP8477 and Omeprazole
Study Start Date : November 2010
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drug Reactions

Arm Intervention/treatment
Experimental: 1. ASP8477 and placebo
Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
Drug: ASP8477
oral

Drug: Placebo
oral

Experimental: 2. ASP8477 alone
Part 3, fasted or fed
Drug: ASP8477
oral

Experimental: 3. omeprazole alone
Part 4, Drug-Drug Interaction
Drug: omeprazole
oral

Experimental: 4. ASP8477 + omeprazole
Part 4: Drug-Drug Interaction
Drug: ASP8477
oral

Drug: omeprazole
oral




Primary Outcome Measures :
  1. Safety as assessed by recording adverse events, physical examination, laboratory assessments, vital signs, electrocardiograms (ECGs), cortisol levels, arterial carbon dioxide and oxygen saturation [ Time Frame: Day1 to End of Study Visit (5-9 days after final discharge) ]
    For Part I and II Bond-Lader Visual Analogue Scale (VAS) and Bowdle VAS assessments will also be taken.

  2. The assessment of pharmacokinetic parameter of ASP8477 measured by Maximum concentration (Cmax), in plasma [ Time Frame: Day 1 to Day 3 ]
    Maximum concentration (Cmax)

  3. The assessment of pharmacokinetic parameter of ASP8477 measured by Time to attain Cmax (tmax) in plasma [ Time Frame: Day 1 to Day 3 ]
    Time to attain Cmax (tmax)

  4. The assessment of pharmacokinetic parameter of ASP8477 measured by Area Under the Curve (AUC) extrapolated until infinity (AUCinf) in plasma [ Time Frame: Day 1 to Day 3 ]
    Area Under the Curve (AUC) extrapolated until infinity (AUCinf)

  5. The assessment of pharmacokinetic parameter of ASP8477 measured by AUC until last sample taken (AUClast) in plasma [ Time Frame: Day 1 to Day 3 ]
    AUC until last sample taken (AUClast), Absorption lag time (tlag), Apparent terminal elimination half-life (t1/2), Apparent volume of distribution (Vz/F), Apparent total body plasma clearance (CL/F)

  6. The assessment of pharmacokinetic parameter of ASP8477 measured by Absorption lag time (tlag) in plasma [ Time Frame: Day 1 to Day 3 ]
    Absorption lag time (tlag)

  7. The assessment of pharmacokinetic parameter of ASP8477 measured by Apparent terminal elimination half-life (t1/2) in plasma [ Time Frame: Day 1 to Day 3 ]
    Apparent terminal elimination half-life (t1/2)

  8. The assessment of pharmacokinetic parameter of ASP8477 measured by Apparent volume of distribution (Vz/F) in plasma [ Time Frame: Day 1 to Day 3 ]
    Apparent volume of distribution (Vz/F)

  9. The assessment of pharmacokinetic parameter of ASP8477 measured by Apparent total body plasma clearance (CL/F) in plasma [ Time Frame: Day 1 to Day 3 ]
    Apparent total body plasma clearance (CL/F)

  10. The assessment of pharmacokinetic parameter of ASP8477 measured by Amount excreted in urine until last sample (Aelast) in urine [ Time Frame: Day 1 to Day 3 ]
    Amount excreted in urine until last sample (Aelast)

  11. The assessment of pharmacokinetic parameter of ASP8477 measured by Cumulative amount of unchanged drug excreted into the urine from time zero to infinity after single dose (Aeinf) in urine [ Time Frame: Day 1 to Day 3 ]
    Cumulative amount of unchanged drug excreted into the urine from time zero to infinity after single dose (Aeinf)

  12. The assessment of pharmacokinetic parameter of ASP8477 measured by Percentage of unchanged drug excreted into the urine from time of last measurable concentration (Aelast%) in urine [ Time Frame: Day 1 to Day 3 ]
    Percentage of unchanged drug excreted into the urine from time of last measurable concentration (Aelast%)

  13. The assessment of pharmacokinetic parameter of ASP8477 measured by Percentage of unchanged drug excreted into the urine from time zero to infinity after single dose (Aeinf%) in urine [ Time Frame: Day 1 to Day 3 ]
    Percentage of unchanged drug excreted into the urine from time zero to infinity after single dose (Aeinf%)

  14. The assessment of pharmacokinetic parameter of ASP8477 measured by Renal clearance (CLR) in urine [ Time Frame: Day 1 to Day 3 ]
    Renal clearance (CLR)


Secondary Outcome Measures :
  1. The assessment of pharmacokinetics of omeprazole measured by plasma concentration [ Time Frame: Day 1 to Day 3 ]
    Cmax, tmax, AUCinf, AUClast, t1/2, Vz/F, CL/F

  2. The assessment of pharmacodynamics of ASP8477 measured by serum concentration [ Time Frame: Day 1 to Day 4 ]
    serum concentration of endogenous substrates, volume of urine production, GFR and intra-ocular pressure



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy young (<65 years of age at first planned dose) postmenopausal female (Parts I, III, and IV).
  • Healthy young vasectomized male subject aged 18-55 years inclusive (Part II).
  • Body Mass index between 18.5 and 30.0 kg/m2 inclusive.

Exclusion Criteria:

  • Known or suspected hypersensitivity to ASP8477 or any of the components of the formulations used.
  • Any of the liver function tests above the upper limit of normal.
  • A family history of psychiatric disorders.
  • Use of grapefruit (more than 3 x 200 ml) or marmalade (more than three times) in the week prior to admission to the Clinical Unit, as reported by the subject.
  • Use of xanthine-containing beverages within 48 hours before admission.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02220777


Locations
Layout table for location information
Belgium
SGS Belgium N.V.
Antwerp, Belgium, B-2060
France
SGS Aster
Paris, France, 75015
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Layout table for investigator information
Study Chair: Study Manager Astellas Pharma Europe B.V.
Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02220777    
Other Study ID Numbers: 8477-CL-0001
2009-017865-42 ( EudraCT Number )
First Posted: August 20, 2014    Key Record Dates
Last Update Posted: August 20, 2014
Last Verified: August 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
MTD (Maximum Tolerated Dose)
Food effect
Postmenopausal subjects
Vasectomized subjects
FIH (First In Humans)
SAD (Single Ascending Dose)
DDI (Drug-Drug Interaction)
Additional relevant MeSH terms:
Layout table for MeSH terms
Omeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action